Free Trial

InMed Pharmaceuticals (INM) Competitors

InMed Pharmaceuticals logo
$2.76 +0.03 (+1.10%)
Closing price 04:00 PM Eastern
Extended Trading
$2.74 -0.02 (-0.91%)
As of 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

INM vs. CTXR, RVPH, PMN, GOVX, PRPH, ALLR, HOTH, LEXX, NKGN, and CASI

Should you be buying InMed Pharmaceuticals stock or one of its competitors? The main competitors of InMed Pharmaceuticals include Citius Pharmaceuticals (CTXR), Reviva Pharmaceuticals (RVPH), Promis Neurosciences (PMN), GeoVax Labs (GOVX), ProPhase Labs (PRPH), Allarity Therapeutics (ALLR), Hoth Therapeutics (HOTH), Lexaria Bioscience (LEXX), NKGen Biotech (NKGN), and CASI Pharmaceuticals (CASI). These companies are all part of the "pharmaceutical products" industry.

InMed Pharmaceuticals vs. Its Competitors

InMed Pharmaceuticals (NASDAQ:INM) and Citius Pharmaceuticals (NASDAQ:CTXR) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, valuation, risk, profitability and institutional ownership.

In the previous week, Citius Pharmaceuticals had 3 more articles in the media than InMed Pharmaceuticals. MarketBeat recorded 5 mentions for Citius Pharmaceuticals and 2 mentions for InMed Pharmaceuticals. InMed Pharmaceuticals' average media sentiment score of 0.32 beat Citius Pharmaceuticals' score of -0.33 indicating that InMed Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
InMed Pharmaceuticals
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Citius Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

InMed Pharmaceuticals has higher revenue and earnings than Citius Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
InMed Pharmaceuticals$4.60M0.73-$7.68M-$12.09-0.23
Citius PharmaceuticalsN/AN/A-$39.14MN/AN/A

InMed Pharmaceuticals has a beta of 0.3, meaning that its stock price is 70% less volatile than the S&P 500. Comparatively, Citius Pharmaceuticals has a beta of 1.23, meaning that its stock price is 23% more volatile than the S&P 500.

20.1% of InMed Pharmaceuticals shares are held by institutional investors. Comparatively, 16.9% of Citius Pharmaceuticals shares are held by institutional investors. 1.4% of InMed Pharmaceuticals shares are held by insiders. Comparatively, 10.7% of Citius Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Citius Pharmaceuticals has a net margin of 0.00% compared to InMed Pharmaceuticals' net margin of -168.87%. Citius Pharmaceuticals' return on equity of -58.63% beat InMed Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
InMed Pharmaceuticals-168.87% -107.93% -82.97%
Citius Pharmaceuticals N/A -58.63%-37.67%

Citius Pharmaceuticals has a consensus price target of $53.00, indicating a potential upside of 2,646.11%. Given Citius Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Citius Pharmaceuticals is more favorable than InMed Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
InMed Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Citius Pharmaceuticals
0 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.80

Summary

Citius Pharmaceuticals beats InMed Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

Get InMed Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for INM and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

INM vs. The Competition

MetricInMed PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$3.34M$2.37B$5.46B$8.92B
Dividend YieldN/A1.78%5.24%4.04%
P/E Ratio-0.238.9127.0120.12
Price / Sales0.73499.49380.1493.35
Price / CashN/A21.7726.2128.59
Price / Book0.134.537.995.57
Net Income-$7.68M$31.26M$3.16B$248.40M
7 Day Performance-10.68%5.57%3.69%6.04%
1 Month Performance-3.83%5.48%2.91%7.69%
1 Year Performance-46.78%1.14%34.30%20.97%

InMed Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
INM
InMed Pharmaceuticals
1.0298 of 5 stars
$2.76
+1.1%
N/A-48.1%$3.34M$4.60M-0.2310Analyst Upgrade
CTXR
Citius Pharmaceuticals
2.4302 of 5 stars
$1.59
+3.9%
$53.00
+3,233.3%
-84.1%$16.27MN/A0.0020High Trading Volume
RVPH
Reviva Pharmaceuticals
2.2651 of 5 stars
$0.38
+12.9%
$9.00
+2,261.6%
-68.6%$16.20MN/A-0.485High Trading Volume
PMN
Promis Neurosciences
3.3528 of 5 stars
$0.48
+0.7%
$4.50
+830.1%
-76.4%$15.70MN/A-9.685Gap Down
GOVX
GeoVax Labs
3.3257 of 5 stars
$0.87
-9.8%
$11.10
+1,182.2%
-82.1%$15.29M$3.95M-0.2410Analyst Downgrade
PRPH
ProPhase Labs
0.7853 of 5 stars
$0.39
+6.6%
N/A-86.4%$15.25M$6.77M-0.31130
ALLR
Allarity Therapeutics
1.1228 of 5 stars
$1.01
+1.0%
N/A-84.1%$15.08MN/A0.0010News Coverage
HOTH
Hoth Therapeutics
1.4145 of 5 stars
$1.17
+3.5%
$4.00
+241.9%
+35.6%$14.93MN/A-1.034Analyst Upgrade
LEXX
Lexaria Bioscience
2.8585 of 5 stars
$0.87
+2.5%
$7.00
+704.6%
-68.0%$14.91M$460K-1.477Upcoming Earnings
NKGN
NKGen Biotech
N/A$0.33
+37.4%
N/A-77.6%$14.83MN/A-0.06N/AGap Down
CASI
CASI Pharmaceuticals
4.106 of 5 stars
$1.18
-1.7%
$4.00
+239.0%
-76.8%$14.76M$28.54M-0.46180Gap Down
High Trading Volume

Related Companies and Tools


This page (NASDAQ:INM) was last updated on 7/8/2025 by MarketBeat.com Staff
From Our Partners